Journal of Headache and Pain

Papers
(The median citation count of Journal of Headache and Pain is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine536
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study267
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition123
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II97
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis93
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study87
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache71
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States69
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries64
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study64
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials62
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation60
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency59
Characteristics of N400 component elicited in patients who have migraine with aura57
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China54
Debate: Are cluster headache and migraine distinct headache disorders?53
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks51
Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome48
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study48
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke46
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia43
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine42
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine42
Measuring interictal burden among people affected by migraine: a descriptive survey study40
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine39
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients38
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey37
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI35
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury35
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States35
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results35
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study34
Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs34
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension33
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials32
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study32
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study30
Correction to: Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic revi30
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting30
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany30
Inflammatory complications of CGRP monoclonal antibodies: a case series30
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas29
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain29
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study28
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study28
Tracking the evolution of non-headache symptoms through the migraine attack27
Development and validation of a novel model for characterizing migraine outcomes within real-world data27
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies27
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients27
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials27
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model27
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study26
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study26
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank26
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study25
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-201925
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients25
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study24
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients24
Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats23
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis23
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)23
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients23
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review22
Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine22
Effects of a history of headache and migraine treatment on baseline neurocognitive function in young athletes22
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab22
Insulin sensitizes neural and vascular TRPV1 receptors in the trigeminovascular system22
Genome-wide analysis identified novel susceptible genes of restless legs syndrome in migraineurs22
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch22
Prenatal oestrogen-testosterone balance as a risk factor of migraine in adults22
Correction: Applying a biopsychosocial model to migraine: rationale and clinical implications22
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury22
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study22
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure22
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study22
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients22
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation22
Interictal osmophobia is associated with longer migraine disease duration21
Long COVID headache21
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts21
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 rece21
Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists20
Long term evaluation of a multidisciplinary trigeminal neuralgia service20
Is there a causal relationship between stress and migraine? Current evidence and implications for management20
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension20
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database20
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience20
The economic and personal burden of cluster headache: a controlled cross-sectional study20
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update19
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis19
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results19
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study18
Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup18
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study18
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms18
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study18
Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan18
Correction to: Hyperbaric oxygen attenuates neuropathic pain and reverses inflammatory signaling likely via the Kindlin-1/Wnt-10a signaling pathway in the chronic pain injury model in rats17
The Global Campaign turns 18: a brief review of its activities and achievements17
TIME, to move forward? comment on “a universal outcome measure for headache treatments, care-delivery systems and economic analysis”17
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study17
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs17
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine17
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine16
A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine16
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study16
The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence16
Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies16
Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache16
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)16
Cortical spreading depression can be triggered by sensory stimulation in primed wild type mouse brain: a mechanistic insight to migraine aura generation16
Comment regarding: what is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta‑analysis of clinical trials16
Correction to: CGRP induces migraine-like symptoms in mice during both the active and inactive phases16
0.071526050567627